Status:
COMPLETED
Bronchopulmonary PK of AT-527 (R07496998)
Lead Sponsor:
Atea Pharmaceuticals, Inc.
Collaborating Sponsors:
Hoffmann-La Roche
Conditions:
Healthy Volunteer Study
Eligibility:
All Genders
18-65 years
Phase:
PHASE1
Brief Summary
This study will assess the safety, tolerability and bronchopulmonary pharmacokinetics (PK) of AT-527 (R07496998)
Eligibility Criteria
Inclusion
- Subjects must agree to use birth control, as required by the protocol.
- Females must have a negative pregnancy test at Screening and prior to dosing
- Minimum body weight of 50 kg and body mass index (BMI) of 18-29 kg/m2
- Willing to comply with the study requirements and to provide written informed consent
Exclusion
- Infected with hepatitis B virus, hepatitis C virus, HIV or SARS-CoV-2
- Abuse of alcohol or drugs
- Use of other investigational drugs within 28 days of dosing
- Concomitant use of prescription medications, or systemic over-the-counter medications
- Other clinically significant medical conditions or laboratory abnormalities
Key Trial Info
Start Date :
April 25 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 31 2021
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT04877769
Start Date
April 25 2021
End Date
August 31 2021
Last Update
February 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Atea Study Site
London, United Kingdom, NW10 7EW